List of Excipients in Branded Drug TRANXENE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	CELLULOSE, MICROCRYSTALLINE
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	FD&C YELLOW NO. 6
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	MAGNESIUM OXIDE
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	MAGNESIUM STEARATE
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	POTASSIUM CARBONATE
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	POTASSIUM CHLORIDE
RECORDATI RARE DISEASES INC	TRANXENE	clorazepate dipotassium	55292-302	SILICON DIOXIDE

TRANXENE Excipient Strategy and Commercial Opportunities: Formulation, Generic, and Patent Analysis

Last updated: August 13, 2026

TRANXENE is the branded product for clorazepate dipotassium, an oral benzodiazepine prodrug indicated for anxiety disorders, adjunctive treatment of partial seizures, and acute alcohol-withdrawal symptoms. Its commercial opportunity is primarily in generic supply, lifecycle reformulation, dosage-form differentiation, and controlled-substance manufacturing capability. The original product has no meaningful remaining market exclusivity, and biosimilar risk is irrelevant because clorazepate is a synthetic small molecule rather than a biologic.[1]

What is TRANXENE and which formulations are commercially relevant?

TRANXENE contains clorazepate dipotassium, which is converted in vivo to desmethyldiazepam, also known as nordazepam. The product is administered orally in capsule or tablet presentations depending on the market and product configuration.[1]

Attribute	TRANXENE / clorazepate dipotassium
Active ingredient	Clorazepate dipotassium
Pharmacologic class	Benzodiazepine
Primary active metabolite	Desmethyldiazepam
U.S. dosage forms	Oral capsules and tablets, depending on listed product
Common strengths	3.75 mg, 7.5 mg, and 15 mg
U.S. controlled-substance status	Schedule IV
FDA pathway for generics	ANDA, subject to reference-product requirements
Biosimilar exposure	None
Main commercial markets	Generic anxiety, seizure adjunct, and alcohol-withdrawal treatment
Key formulation constraints	Dose uniformity, capsule or tablet performance, dissolution, moisture control, and controlled-substance compliance

The active drug is supplied as a dipotassium salt and is highly suitable for conventional immediate-release oral solid dosage forms. The prodrug mechanism does not require an extended-release delivery system for the approved TRANXENE indications. That limits the value of complex delivery technology but reduces development cost for generic and reformulated products.

What excipients are used in TRANXENE and what functions do they perform?

The current reference-product label and individual generic labels should be treated as the controlling sources for exact inactive-ingredient composition. Excipients may differ among strengths, manufacturers, and dosage forms. FDA’s Inactive Ingredient Database is the principal tool for assessing prior-use precedent and route-specific exposure.[2]

For a clorazepate immediate-release product, the excipient strategy generally needs to address the following functions:

Formulation function	Candidate excipient classes	Commercial purpose
Dilution and content uniformity	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Supports low-dose API distribution
Lubrication	Magnesium stearate, sodium stearyl fumarate	Improves manufacturing efficiency
Flow improvement	Colloidal silicon dioxide, talc	Reduces segregation and improves powder handling
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports immediate-release dissolution
Capsule shell	Gelatin or hypromellose	Enables capsule presentation and vegetarian positioning
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves appearance, identification, and handling
Moisture control	Low-moisture excipient grades, protective packaging, desiccants	Limits hydrolytic and physical instability
Taste and swallowability	Film coating, capsule shell, taste-masking polymers	Relevant for geriatric and adherence-focused products

Which excipient risks are specific to clorazepate?

The principal technical risk is not novel chemistry. It is reproducible delivery of a low-dose benzodiazepine in a conventional solid dosage form.

A 3.75-mg strength creates a greater content-uniformity challenge than the 15-mg strength. A formulation with excessive API dilution, poor powder flow, or segregation can produce unacceptable unit-to-unit variability. Direct compression may be commercially attractive, but wet granulation can provide better blend uniformity if the selected excipient system creates flow or segregation problems.

Moisture management also matters. Clorazepate dipotassium is a salt-based prodrug, and the finished product must be evaluated for potency, degradants, dissolution, and physical changes under accelerated and long-term conditions. The optimal excipient package should be selected through compatibility screening rather than by copying a reference formulation.

Excipient changes can affect:

• Assay and content uniformity.
• Dissolution and disintegration.
• Capsule fill weight and powder flow.
• Stability and impurity formation.
• Bioequivalence risk.
• Labeling for lactose, gluten, gelatin, titanium dioxide, and other excipient concerns.
• Manufacturing cost and supplier concentration.

What excipient strategy offers the strongest commercial opportunity?

The strongest near-term strategy is a low-cost, immediate-release generic platform with a common blend across the 3.75-mg, 7.5-mg, and 15-mg strengths.

Strategy 1: Common-blend immediate-release capsules

A common blend can reduce manufacturing complexity and simplify scale-up. The product developer should optimize the formulation around:

1. A high-uniformity API premix.
2. A filler system that supports low-dose distribution.
3. A robust disintegrant level.
4. Low lubricant sensitivity.
5. Capsule-filling performance across all strengths.

This approach is suitable for ANDA development where the objective is to match the reference product’s release profile without introducing unnecessary formulation complexity.

Strategy 2: Lactose-free or low-allergen formulation

A lactose-free product can target patients with lactose intolerance and institutional buyers seeking simplified excipient labeling. Microcrystalline cellulose, mannitol, or dibasic calcium phosphate can replace lactose, subject to manufacturability and bioequivalence performance.

This is a differentiation strategy rather than a strong patent moat. The commercial value depends on payer access, pharmacy substitution, and whether the product can maintain a competitive cost of goods.

Strategy 3: Hypromellose capsule or film-coated tablet

A hypromellose capsule can support vegetarian positioning and reduce reliance on gelatin. A film-coated tablet may improve swallowability, reduce powder exposure, and create a more differentiated appearance.

Neither option inherently creates strong exclusivity. Patent value would depend on a specific, non-obvious combination that produces an unexpected stability, dissolution, or manufacturing result.

Strategy 4: Low-moisture formulation and packaging

A moisture-controlled product may provide a practical quality advantage in high-humidity markets. Useful measures include:

• Low-moisture excipient grades.
• High-barrier blister packaging.
• Desiccant-containing bottles.
• Nitrogen flushing where justified.
• Tight container-closure specifications.
• Stability testing across multiple climatic zones.

The commercial opportunity is strongest outside tightly commoditized U.S. retail channels, where supply reliability and shelf-life performance can carry more value.

What patents protect TRANXENE and when does exclusivity end?

The original TRANXENE product is an old small-molecule benzodiazepine product. Its original composition, use, and product exclusivity periods expired long ago. No meaningful active patent barrier is expected to block ordinary generic development of clorazepate dipotassium immediate-release products.

Exclusivity category	TRANXENE status
New chemical entity exclusivity	Expired
Original product patent protection	Expired or otherwise no longer commercially blocking
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current blocking period
Reference-product exclusivity	Expired
Biosimilar exclusivity	Not applicable
Current formulation patent barrier	No broadly recognized blocking barrier for standard immediate-release products

A current Orange Book review should distinguish between patents listed for a specific NDA and patents that could affect a proposed generic product. An old, expired listing does not prevent ANDA approval. FDA’s Orange Book remains the controlling public database for listed patents, exclusivity, and reference-product information.[3]

What is the FDA regulatory status of TRANXENE and clorazepate generics?

Clorazepate is regulated as a prescription controlled substance. FDA approval of a generic product requires pharmaceutical equivalence, bioequivalence, adequate chemistry and manufacturing controls, and compliance with controlled-substance requirements. The product must also satisfy Drug Enforcement Administration requirements for handling, storage, recordkeeping, and distribution.[4]

The standard regulatory route is an ANDA when the proposed product matches the reference product in active ingredient, dosage form, strength, route, and relevant performance characteristics. A formulation that changes the dosage form, release profile, or clinical use may require a different regulatory strategy.

Development route	Use case	Risk profile
ANDA	Conventional immediate-release generic	Lowest development complexity
505(b)(2) application	Modified formulation or new delivery approach	Higher clinical and regulatory burden
New NDA	Novel clinical or delivery proposition	Highest cost and market risk
OTC switch	Not commercially realistic for this controlled benzodiazepine	Very high regulatory barrier

What formulation patents could create defensible value?

A simple lactose substitution, capsule-color change, or excipient replacement is unlikely to provide durable patent protection. A stronger formulation patent would need to claim a specific technical result, such as:

• A stable clorazepate formulation with a defined impurity profile.
• A low-dose blend with demonstrated content-uniformity performance.
• A moisture-resistant dosage form with extended shelf life.
• A multiparticulate product with a controlled release profile.
• A tamper-resistant dosage form that limits powder extraction or crushing.
• A novel capsule or tablet architecture that improves dose flexibility.
• A pediatric or geriatric dosage form with clinically relevant administration benefits.

Method-of-use patents are also possible, but their value is limited by the age of the molecule, established clinical use, and the ability of generic applicants to carve out patented indications from labeling. Any new use would require credible clinical evidence and a commercially material treatment population.

Which companies are challenging TRANXENE, and what is the litigation status?

Clorazepate is a mature generic market with multiple manufacturers and no widely recognized, active patent litigation comparable to the litigation surrounding newer branded medicines. Generic competition is generally driven by ANDA approvals, supply reliability, wholesaler contracts, controlled-substance capacity, and price.

Paragraph IV litigation risk is low for ordinary clorazepate products because the original patent estate is expired. A Paragraph IV certification could still arise if a newer patent were listed for a specific formulation or use, but a standard immediate-release generic is unlikely to face a substantial current patent challenge.

No biosimilar litigation exists because TRANXENE is not a biologic. Product liability and controlled-substance compliance issues are more commercially relevant than patent litigation.

What generic launch risks exist for clorazepate?

The principal launch risks are operational and commercial:

Supply and manufacturing risk

Controlled-substance manufacturers require secure inventory controls, quota management, and compliant distribution systems. A company without existing Schedule IV infrastructure may face higher launch costs and slower commercialization.

Market-size risk

Clorazepate is a mature, relatively narrow market. Demand is divided among generic benzodiazepines, including diazepam, lorazepam, alprazolam, and clonazepam. A new entrant may gain limited share unless it offers a supply, formulation, or channel advantage.

Substitution risk

Pharmacy substitution generally favors the lowest-cost approved generic. A premium excipient proposition will have limited value unless it solves a clear problem, such as lactose avoidance, capsule acceptability, availability, or institutional procurement requirements.

Clinical and safety risk

The class carries dependence, withdrawal, sedation, misuse, and respiratory-depression concerns, particularly with opioids or other central nervous system depressants. These risks influence prescribing and may limit market expansion even when the product is inexpensive.[1]

How does TRANXENE compare with competing benzodiazepines?

Product	Active ingredient	Typical commercial position	Differentiation opportunity
TRANXENE	Clorazepate dipotassium	Mature oral generic	Supply reliability, lactose-free or geriatric formulation
Valium	Diazepam	Broad legacy use; generic competition	Low-cost supply and dosage-form breadth
Ativan	Lorazepam	Common acute anxiety and seizure use	Institutional supply and injectable competition
Xanax	Alprazolam	High-volume anxiety market	Stronger demand but greater competition and abuse scrutiny
Klonopin	Clonazepam	Anxiety and seizure treatment	Established prescriber familiarity
Librium	Chlordiazepoxide	Alcohol withdrawal and legacy anxiety use	Institutional and alcohol-withdrawal channel

Clorazepate has a longer-acting metabolite profile than some shorter-acting benzodiazepines. That characteristic may support particular prescriber preferences, but it can also increase concern about accumulation, sedation, and withdrawal management. Excipient differentiation will not overcome weak clinical positioning or limited market demand.

What licensing and partnership opportunities exist?

The most practical licensing opportunities are manufacturing and distribution agreements rather than rights to a valuable active patent estate.

Potential structures include:

• Contract manufacturing of capsules or tablets for regional generic companies.
• Licensing of a moisture-resistant formulation.
• Supply agreements with hospital and behavioral-health distributors.
• Co-development of a controlled-substance portfolio.
• Regional commercialization rights in markets where clorazepate remains listed or clinically used.
• Packaging and serialization partnerships for controlled-substance products.

A formulation license is commercially credible only if it includes validated stability data, scalable manufacturing, regulatory documentation, and a measurable cost or quality advantage. A patent-only license without manufacturing or regulatory assets is unlikely to command significant value.

How strong is the TRANXENE patent estate?

The patent estate is weak from a lifecycle-management perspective because the product is old, genericized, and based on a conventional oral small-molecule formulation. Its commercial defensibility depends on execution rather than exclusivity.

Patent-estate factor	Assessment
Core molecule protection	Expired
Original use protection	Expired
Standard immediate-release formulation	Low defensibility
New excipient combination	Potentially patentable, but evidence-dependent
Manufacturing process	Possible narrow protection
Controlled-release reformulation	Higher technical and regulatory burden
Regulatory exclusivity	No current material protection expected
Litigation leverage	Low for conventional generic products
Commercial moat	Manufacturing, supply, contracting, and quality systems

Key Takeaways

• TRANXENE is clorazepate dipotassium, an established Schedule IV benzodiazepine prodrug.
• The original patent and regulatory exclusivity position is expired; ordinary generic entry does not face a meaningful legacy patent barrier.
• The best excipient strategy is a robust immediate-release platform that supports dose uniformity across 3.75-mg, 7.5-mg, and 15-mg strengths.
• Lactose-free, hypromellose-capsule, film-coated, and moisture-controlled products provide commercial differentiation but limited intrinsic exclusivity.
• New patents would need to claim a specific formulation, stability, manufacturing, or delivery advantage.
• Biosimilar risk is irrelevant.
• Commercial success depends mainly on controlled-substance manufacturing, supply reliability, contracting, cost of goods, and regulatory execution.
• Licensing value is more likely to arise from manufacturing and regional commercialization rights than from the legacy TRANXENE patent estate.

FAQs About TRANXENE Excipient and Commercial Strategy

Can a lactose-free clorazepate product be developed as a generic?

Yes. A lactose-free formulation can use alternative fillers such as microcrystalline cellulose, mannitol, or dibasic calcium phosphate, subject to pharmaceutical equivalence, bioequivalence, stability, and manufacturing validation.

Is a new clorazepate excipient combination patentable?

Potentially, but routine excipient substitution is unlikely to provide strong protection. Patentability improves when the formulation demonstrates an unexpected stability, dissolution, uniformity, or abuse-deterrence result.

Does TRANXENE require an extended-release formulation?

No. Approved TRANXENE products are conventional oral products. An extended-release version would create a separate development and regulatory program rather than a straightforward generic substitution.

Can clorazepate be commercialized without controlled-substance manufacturing capability?

A sponsor would need an appropriately qualified contract manufacturer or its own compliant controlled-substance operations. Schedule IV handling requirements affect manufacturing, warehousing, distribution, and recordkeeping.

Is a pediatric TRANXENE formulation a realistic opportunity?

It is technically possible, but the opportunity is constrained by benzodiazepine safety concerns, controlled-substance requirements, clinical evidence needs, and the limited size of the target market. An age-appropriate liquid or dispersible product would require a clear clinical or adherence benefit.

References

1. U.S. Food and Drug Administration. (n.d.). TRANXENE (clorazepate dipotassium) prescribing information. FDA/DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. https://www.deadiversion.usdoj.gov/schedules/gi-dea.html